This is where you will find information on the latest updates to the National Clinical Terminology Service products and resources. The details of any changes are included in the relevant release note.
|/news-and-events/snomed-ct-au-30-september-2022-release-note/||SNOMED CT-AU Release Note 30 September 2022|
|/library/DH_3647_2022_NCTS_DocumentLibraryReleaseNote_v2.30.pdf||NCTS Document Library Release Note v2.30|
|/library/DH_3596_2022_RCPA_PathologyTerminologyandInformationModels_ReleaseNote_v1.6.pdf||RCPA Pathology Terminology and Information Models Release Note v1.6|
|/library/DH_3467_2021_RCPA_StructuredPathologyReportingofCancerFHIRReferenceSets_ReleaseNote_v1.0.pdf||RCPA Structured Pathology Reporting of Cancer FHIR Reference Sets Release Note v1.0|
LOINC (updated August 2022)
The LOINC release version 2.73 is now available from the National Clinical Terminology Server.
RCPA – SPIA Requesting Pathology Terminology Reference Set (updated February 2022)
The Royal College of Pathologists of Australasia Standards for Pathology Informatics in Australia Requesting Pathology reference set has been updated to version 4.2.
ACT Reportable Schedule 4 medications reference set (added September 2021)
Produced by ACT Health, the ACT Reportable Schedule 4 medications reference set supports the identification of the AMT TPUU, CTPP, MPP and MPUU concepts associated with Schedule 4 medicines that are monitored by ACT Health Canberra Script Real-Time Prescription Monitoring (RTPM) solution. This reference set can be used by applications to identify Schedule 4 medicines that are to be monitored in support of the ACT Health Canberra Script system’s requirements.
Vaccination Recommendation Status reference set (added August 2021)
The Vaccination recommendation status reference set supports the recording of vaccination statuses for vaccine administration recommendations. This reference set can be used within any implementation that records vaccination statuses as part of vaccine administration recommendations.
NT Reportable Schedule 4 medications reference set (added June 2021)
The Northern Territory Reportable Schedule 4 medications reference set supports the identification of the AMT TPUU, CTPP, MPUU and MPP concepts that are reportable within the Northern Territory. This reference set can be used by applications to identify reportable Schedule 4 medications that are to be monitored in support of the Northern Territory Government Department of Health NTScript system’s requirements.
List of Excluded Medicinal Items reference set (added May 2021)
The List of Excluded Medicinal Items reference set supports the identification of AMT MPUU and MPP concepts associated with the List of Excluded Medicinal Items (LEMI) under The National Health (Pharmaceutical Benefits) Amendment (Active Ingredient Prescribing) Regulations 2019 and The Veterans’ Affairs Pharmaceutical Benefits Schemes (Electronic Prescriptions and Active Ingredient Prescribing) Amendment Instrument 2019. This reference set can be used by prescribing software vendors to identify medicinal items listed on the Pharmaceutical Benefits Scheme and Repatriation Pharmaceutical Benefits Scheme that are excluded from the Active Ingredient Prescribing requirements.
RCPA – Structured Pathology Reporting of Cancer FHIR Reference Sets (added May 2021)
This new bundle contains draft FHIR reference set resources developed and owned by the Royal College of Pathologists of Australaisa (RCPA), and includes:
- RCPA SPRC Cervical Cancer FHIR Reference Set dv001
- RCPA SPRC Colorectal Cancer FHIR Reference Set dv001
- RCPA SPRC Endometrial Cancer FHIR Reference Set dv001
- RCPA SPRC Carcinoma of the Ovary, Fallopian Tube and Primary Peritoneal Site FHIR Reference Set dv001
- RCPA SPRC Polypectomy and Local Resections of the Colorectum FHIR Reference Set dv001
For more information and to access these resources please refer to the RCPA – Structured Pathology Reporting of Cancer FHIR Reference Sets Release Note under RCPA resources.
NSW Reportable Schedule 4 reference set (added February 2021)
This newly released reference set supports systems with the identification of the AMT Trade Product Unit of Use (TPUU), Containered Trade Product Pack (CTPP), Medicinal Product Unit of Use (MPUU) and Medicinal Product Pack (MPP) concepts that are reportable within New South Wales for Real Time Reporting (RTR) and Real Time Prescription Monitoring (RTPM) requirements.
This reference set complements the existing reportable Schedule 4 reference sets and the Schedule 8 medications reference set.
Black Triangle Scheme reference set (added December 2020)
This newly release reference set supports the identification of AMT Trade Product Unit of Use (TPUU) and Containered Trade Product Pack (CTPP) concepts that are associated with medicines where reporting adverse events are encouraged under the Black Triangle Scheme run by the Therapeutic Goods Administration. This reference set can be used by prescribing and dispensing software vendors to identify medications where reporting of adverse events is encouraged under the Black Triangle Scheme. Further details be found in the SNOMED CT-AU Development Approach for Reference Sets v3.4.
List of Medicines for Brand Consideration reference set (added September 2020)
This reference set has been updated to include additional medicines as notified by the Australian Government Department of Health. This reference set enables software vendors to identify AMT Medicinal Product Unit of Use (MPUU) and Medicinal Product Pack (MPP) concepts associated with the List of Medicines for Brand Consideration (LMBC).
The following list contains all COVID-19 specific concepts that are currently available in the SNOMED CT-AU release. They are displayed below as concept ID |Preferred Term| and grouped according to their SNOMED CT concept hierarchy. You can view any additional synonyms to these concepts in the Shrimp Terminology Browser. Recent additions from the July 2021 SNOMED International release can be viewed in the SNOMED CT-AU September 2021 release note. If you have suggestions for new concepts or synonyms, please complete our online request form (preferred) or send your content request to firstname.lastname@example.org.
Australian Medicines Terminology
The following list only includes the Medicinal Product (MP) and associated Containered Trade Product Pack (CTTP).
1595591000168104 | COVID-19 (NVX-CoV2373) vaccine | added February 2022
1595641000168108 | Nuvaxovid Multidose injection, 10 x 5 mL vials | added February 2022
1527311000168101 | COVID-19 ChAdOx1-S viral vector vaccine | added February 2021
1530551000168109 | Vaxzevria Multidose injection, 10 x 4 mL vials | (previously COVID-19 Vaccine (AstraZeneca)) added February 2021
1527361000168103 | Vaxzevria Multidose injection 10 x 5 mL vials | (previously COVID-19 Vaccine (AstraZeneca)) added February 2021
1565221000168102 | elasomeran | added August 2021
1565271000168101 | Spikevax Multidose 200 microgram/mL injection, 10 x 5 mL vials | added August 2021
1592411000168100 | regdanvimab | added January 2022
1592461000168101 | Regkirona 960 mg/16 mL injection, 16 mL vial | added January 2022
1480741000168100 | remdesivir | added July 2020
1480881000168101 | Veklury 100 mg powder for injection, 1 vial | added July 2020
1480791000168108 | Veklury 100 mg/20 mL injection, 20 mL vial | added July 2020
1525021000168100 | tozinameran | (previously COVID-19 mRNA vaccine) added February 2021
1525071000168104 | Comirnaty Purple Cap Multidose injection, 195 x 0.45 mL vials | added February 2021
1591901000168100 | Comirnaty Grey Cap 12 Years and Above Ready to Use Multidose 30 microgram/0.3 mL injection, 10 x 2.25 mL vials | added January 2022
1591951000168101 | Comirnaty Grey Cap 12 Years and Above Ready to Use Multidose 30 microgram/0.3 mL injection, 195 x 2.25 mL vials | added January 2022
1591741000168101 | Comirnaty Orange Cap 5 to less than 12 Years Dilute to Use Multidose injection, 10 x 1.3 mL vials | added January 2022
1591771000168108 | Comirnaty Orange Cap 5 to less than 12 Years Dilute to Use Multidose injection, 195 x 1.3 mL vial | added January 2022
1454671000168104 |Recent travel to high risk COVID-19 region|
1465981000168100 |Bilateral interstitial pneumonia| added May 2020
1466021000168105 |Concern about exposure to COVID-19| added May 2020
1466151000168103 |More than two diffuse B-lines on ultrasound of lung| added May 2020
840544004 |Suspected COVID-19|
840546002 |Exposure to COVID-19|
840533007 |SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2)|
840534001 |COVID-19 vaccination|
1454651000168108 |COVID-19 serology|
1454581000168100 |Bronchoalveolar lavage fluid COVID-19 nucleic acid assay|
1454561000168109 |Sputum COVID-19 nucleic acid assay|
1454491000168101 |Oropharyngeal swab COVID-19 nucleic acid assay|
1454411000168105 |Nasopharyngeal swab COVID-19 nucleic acid assay|
1454401000168107 |Home isolation|
1462681000168102 |Rapid COVID-19 antibody detection test|
1462701000168104 |COVID-19 IgM measurement|
1462741000168102 |COVID-19 IgG measurement|
1466171000168107 |ARDSNet Mechanical Ventilation Protocol| added May 2020
1466161000168101 |Permissive hypercapnia ventilation| added May 2020
1466191000168108 |Pleural fluid COVID-19 nucleic acid assay| added May 2020
1466181000168105 |Saliva COVID-19 nucleic acid assay| added May 2020
1480481000168103 | COVID-19 viral culture | added July 2020
1454661000168105 |COVID-19 Clinic and Testing Centre|
840536004 |Antigen of SARS-CoV-2|
840535000 |Antibody to SARS-CoV-2|
By operation of the Public Governance, Performance and Accountability (Establishing the Australian Digital Health Agency) Rule 2016, on 1 July 2016, all the assets and liabilities of NEHTA will vest in the Australian Digital Health Agency. In this website, on and from 1 July 2016, all references to “National E-Health Transition Authority” or “NEHTA” will be deemed to be references to the Australian Digital Health Agency.